2022 Medicare Part B Premium Increase Attributable to Alzheimer’s Drug Aduhelm Will Be Adjusted and Incorporated Into Upcoming 2023 Medicare Premium Determination
Today, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra announced that Medicare Part B premiums paid by Medicare beneficiaries for 2022 should be adjusted downward to account for an overestimate in costs attributable to the inclusion of new Alzheimer’s drug Aduhelm within the Medicare program for reimbursement. Due to the legal and […]